Overly Aggressive Prialt Dose Data Are Not Surrogate Endpoints, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Elan had proposed accelerated approval of the intractable pain therapy in lieu of an agency-requested third pivotal trial, agency review documents show.